Breaking Barriers: Safely Targeting Obstructive Hypertrophic Cardiomyopathy at the Source : Episode 3

Opinion

Video

May 30, 2024

Aligning With 2023 ESC Guidelines in oHCM Treatment

Author(s):

Anjali Tiku Owens, MD

Anjali Tiku Owens, MD, explores the role of cardiac myosin inhibitors in the treatment strategies for patients with obstructive hypertrophic cardiomyopathy (oHCM), in accordance with the latest European Society of Cardiology (ESC) Guidelines released in 2023.

EP: 1.Novel Cardiac Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause

EP: 2.Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment

EP: 3.Aligning With 2023 ESC Guidelines in oHCM Treatment

EP: 4.Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes

EP: 5.Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice

Where do cardiac myosin inhibitors fit into the treatment plans of your patients with oHMC, according to the most recent guidelines? ESC Guidelines 2023

Initiating cardiac myosin inhibitors earlier?
Use in patients who are severely symptomatic?
MAPLE-HCM trial

Related Videos

3 experts are featured in this series.

3 experts are featured in this series.

Advocating for Race-Neutral Approach to Pulmonary Function Testing with Meredith McCormack, MD, and Loretta Que, MD

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.